Accordingly, blast progression (BP) following HMA therapy failure in patients with MDS invariably coincided with the expansion of the CD34+CD38− HSC compartment (Fig. 2c) in the absence of significant changes in BM cellularity (Extended Data Fig. 8a). The gene discussed is CD38; the disease is myelodysplastic syndrome.